Barclays Maintains Overweight on CVS Health, Lowers Price Target to $89
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Steve Valiquette has maintained an Overweight rating on CVS Health (NYSE:CVS) but lowered the price target from $90 to $89.
July 12, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays has maintained an Overweight rating on CVS Health but lowered the price target from $90 to $89.
The news is directly about CVS Health. Barclays' decision to maintain an Overweight rating indicates a positive outlook for the company. However, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100